Capital International Investors acquired a new position in shares of Juno Therapeutics Inc (NASDAQ:JUNO) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 5,714,198 shares of the biopharmaceutical company’s stock, valued at approximately $256,339,000. Capital International Investors owned about 5.00% of Juno Therapeutics at the end of the most recent quarter.
Several other large investors also recently modified their holdings of JUNO. Teachers Advisors LLC increased its holdings in shares of Juno Therapeutics by 15.4% in the 2nd quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock valued at $2,219,000 after acquiring an additional 9,890 shares during the period. DekaBank Deutsche Girozentrale increased its stake in Juno Therapeutics by 27.9% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 61,900 shares of the biopharmaceutical company’s stock valued at $1,712,000 after buying an additional 13,500 shares during the period. Northern Trust Corp grew its stake in shares of Juno Therapeutics by 11.8% during the 2nd quarter. Northern Trust Corp now owns 382,631 shares of the biopharmaceutical company’s stock worth $11,438,000 after purchasing an additional 40,468 shares during the period. Candriam Luxembourg S.C.A. purchased a new stake in shares of Juno Therapeutics in the 3rd quarter worth about $5,428,000. Finally, Sivik Global Healthcare LLC purchased a new stake in shares of Juno Therapeutics in the 3rd quarter worth about $2,467,000. Institutional investors and hedge funds own 69.94% of the company’s stock.
Shares of Juno Therapeutics Inc (NASDAQ JUNO) traded up $1.64 on Tuesday, hitting $47.35. The stock had a trading volume of 1,300,000 shares, compared to its average volume of 2,300,000. The firm has a market capitalization of $5,410.00 and a price-to-earnings ratio of -13.97. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics Inc has a 52 week low of $18.80 and a 52 week high of $63.45.
Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.07. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. Juno Therapeutics’s revenue was up 115.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.57) earnings per share. research analysts expect that Juno Therapeutics Inc will post -4.02 earnings per share for the current fiscal year.
Several equities research analysts recently commented on JUNO shares. Wells Fargo & Co reiterated an “outperform” rating and issued a $54.00 price objective (up from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. Barclays started coverage on shares of Juno Therapeutics in a report on Wednesday, September 6th. They set an “overweight” rating and a $55.00 price objective on the stock. Raymond James Financial increased their price objective on shares of Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a report on Friday, November 3rd. Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, Citigroup reissued a “buy” rating and set a $59.00 target price on shares of Juno Therapeutics in a research report on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the stock. Juno Therapeutics presently has an average rating of “Hold” and a consensus price target of $45.48.
In other Juno Therapeutics news, EVP Robert Azelby sold 1,816 shares of Juno Therapeutics stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $44.96, for a total value of $81,647.36. Following the transaction, the executive vice president now directly owns 70,832 shares of the company’s stock, valued at approximately $3,184,606.72. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Steve Harr sold 8,750 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $44.76, for a total value of $391,650.00. Following the sale, the chief financial officer now owns 772,082 shares in the company, valued at $34,558,390.32. The disclosure for this sale can be found here. Insiders have sold a total of 53,232 shares of company stock valued at $2,450,954 over the last 90 days. Corporate insiders own 15.08% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.truebluetribune.com/2018/01/03/capital-international-investors-buys-new-position-in-juno-therapeutics-inc-juno-3.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.